Synlett 2003(12): 1856-1858  
DOI: 10.1055/s-2003-41498
LETTER
© Georg Thieme Verlag Stuttgart · New York

Model Studies Towards the Total Synthesis of the Anticancer Agent Roseophili­n

E. M. E. Viseuxa, P. J. Parsons*a, J. B. J. Paveyb, C. M. Cartera, I. Pintoc
a The Chemical Laboratories, School of Chemistry, Physics & Environmental Science, University of Sussex, Falmer, Brighton, East Sussex BN1 9QJ, UK
e-Mail: P.J.Parsons@sussex.ac.uk;
b AstraZeneca R&D Charnwood, Process R&D, Bakewell Road, Loughborough, Leics LE11 5RH, UK
c Medicinal Chemistry, GlaxoSmithKline, New Frontiers Science Park (North), Harlow, Essex CM19 5AW, UK
Further Information

Publication History

Received 21 March 2003
Publication Date:
19 September 2003 (online)

Abstract

In our new approach to the anticancer agent roseophilin (1), a concise, stereocontrolled synthesis of the bicyclic model system 16 was achieved. Key steps include a diastereoselective Ireland-Claisen rearrangement and a stereoselective construction of the hexahydro-cyclopenta[b]pyrrol-6-one core via a tandem intramolecular aza-Wittig/[3+2]-cycloaddition sequence.

24

The use of LHMDS seems to favour the E-enolate and the addition of triethylamine to the trimethylsilyl chloride enhances its reactivity.

26

NOE studies of compound 16 (Figure [3] ).

Figure 3